Figure 3
From: ITF2357 transactivates Id3 and regulate TGFβ/BMP7 signaling pathways to attenuate corneal fibrosis
In vivo topical treatment of ITF2357 decreases anterior stromal reflectivity and reduced clinical haze.
Confocal biomicroscopy images from wk 1 to 4 in (A–D) −9.0D photorefractive keratectomy (PRK), (E-H) PRK +0.2% ITF2357 and (I–L) PRK +0.02% MMC treated rabbits. (D) Maximum corneal haze was observed in wk 4, which was decreased by application of (H) ITF2357 and (L) MMC. (I–L) Fewer keratocytes were observed in the anterior stromal bed in MMC treated corneas. (M) Mean gray value analysis of confocal images showed maximum haze in PRK group at wk 3 and wk 4 (*p < 0.05 for wk 3 and ***p < 0.001 for wk 4 against control group). ITF2357 and MMC treatment significant reduced mean gray value by wk 3 and wk 4 (##p < 0.01 against PRK of wk 3 and wk 4 groups). Representative slit lamp microscopy images of corneal haze 4 wk after (N) PRK, (O) PRK + ITF2357 and (P) PRK + MMC rabbits showed similar reduction of clinical haze in MMC and ITF2357 treated corneas. (Q) Clinical grading of corneal haze over 4 wk post-PRK showed significant decrease in haze mean score after 1 month in both ITF2357 and MMC groups (##p < 0.01 against PRK group). There were six rabbits in each group and error bars represent SEM.
